Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p1-10-07
Abstract: Background: Most patients diagnosed with breast cancer have ER+ tumors. Treatment of ER+ MBC typically involves endocrine therapy, including aromatase inhibitors and selective ER modulators such as tamoxifen; however, many patients develop resistance. Fulvestrant, an… read more here.
Keywords: 486 fulvestrant; treatment; breast cancer; cancer ... See more keywords
Initial safety results from a randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e15152
Abstract: e15152Background: Standard adjuvant therapy for colorectal cancer (CRC) is fluoropyrimidine or FOLFOX. The stage IIIC relapse rate is high with a median 5 year survival of only 28%. The multi-kinas... read more here.
Keywords: colorectal cancer; results randomized; initial safety; safety results ... See more keywords